Schlager S I, Dray S
Isr J Med Sci. 1976 Apr-May;12(4-5):344-59.
Two novel immunotherapeutic regimens were developed for a uniformly lethal, intradermally growing transplantable ascites variant (line 10) of a diethylnitrosamine-induced hepatoma in strain 2 guinea pigs. In an apparently tumor-specific immunotherapy model, 32 guinea pigs were cured by the injection into the tumor area, five or seven days after tumor challenge, of syngeneic or xenogeneic RNA extracts obtained from lymphoid tissues of line 10-immune strain 2 guinea pigs or rhesus monkeys, as part of a total regimen which included syngeneic nonsensitive peritoneal exudate cells injected prior to, and tumor-specific antigen injected after, the RNA. In another immunotherapy model, not tumor-specific, 18 strain 2 guinea pigs were cured by the injection into the tumor area, 6 and 16 days after tumor challenge, of antibody specific for fibrin fragment E (FFE), an essential component in the formation of a fibrin matrix considered to be important in tumor development. When therapy was delayed to 12 days in the RNA test system, or to 16 days in the anti-FFE test system, complete abrogation of the tumors did not occur. The long-term survival of the 50 successfully treated animals and their immunity to further tumor challenge indicated that both immunotherapeutic procedures had systemic effects. To test this further, line 10 cells were injected intradermally simultaneously at two sites and only one site was treated. When the one tumor location was treated with anti-FFE, complete regression of the treated tumor and a 30% retardation in the development of the untreated tumor were observed. When this tumor location was treated with the RNA regimen, complete regression of the tumors occurred at both the treated and the untreated sites. Optimal conditions for both immunotherapeutic models and their combination have yet to be establshed. Nonetheless, both immunotherapeutic regimens were more effective than any other immunotherapy thus far reported for this tumor, including the use of BCG or its derivatives.
针对二乙基亚硝胺诱导的2系豚鼠肝癌的一种致死性、皮内生长的可移植腹水变体（10号线），研发了两种新型免疫治疗方案。在一个明显具有肿瘤特异性的免疫治疗模型中，32只豚鼠在肿瘤攻击后5天或7天，通过向肿瘤区域注射从10号线免疫的2系豚鼠或恒河猴的淋巴组织中获得的同基因或异种RNA提取物而治愈，这是整个治疗方案的一部分，该方案包括在RNA注射之前注射同基因非敏感腹膜渗出细胞，以及在RNA注射之后注射肿瘤特异性抗原。在另一个非肿瘤特异性的免疫治疗模型中，18只2系豚鼠在肿瘤攻击后6天和16天，通过向肿瘤区域注射对纤维蛋白片段E（FFE）特异的抗体而治愈，FFE是纤维蛋白基质形成中的一个重要成分，而纤维蛋白基质被认为在肿瘤发展中起重要作用。当在RNA测试系统中将治疗延迟至12天，或在抗FFE测试系统中将治疗延迟至16天时，肿瘤并未完全消除。50只成功接受治疗的动物的长期存活及其对进一步肿瘤攻击的免疫力表明，这两种免疫治疗程序都具有全身效应。为了进一步验证这一点，在两个部位同时皮内注射10号线细胞，仅对其中一个部位进行治疗。当用抗FFE治疗其中一个肿瘤部位时，观察到治疗的肿瘤完全消退，未治疗的肿瘤生长延迟30%。当用RNA方案治疗该肿瘤部位时，治疗部位和未治疗部位的肿瘤均完全消退。这两种免疫治疗模型及其联合应用的最佳条件尚未确定。尽管如此，这两种免疫治疗方案都比迄今为止报道的针对该肿瘤的任何其他免疫治疗方法更有效，包括使用卡介苗或其衍生物。
